PSYENCE BIOMEDICAL LTD (PBM)

CA74449F1009 - Common Stock

0.6  +0 (+0.33%)

After market: 0.7705 +0.17 (+28.42%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PSYENCE BIOMEDICAL LTD

NASDAQ:PBM (6/20/2024, 3:59:09 PM)

After market: 0.7705 +0.17 (+28.42%)

0.6

+0 (+0.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 MonthN/A
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap8.03M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

PBM Daily chart

Company Profile

Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Company Info

PSYENCE BIOMEDICAL LTD

121 Richmond Street West Penthouse, Suite 1300

TORONTO ONTARIO V6E 3Z3

P: 17744604171

CEO: John Plourde

Employees: 0

Website: http://psyence.com

PBM News

ChartMill News Image14 minutes ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

News Imagea month ago - Psyence Biomedical Ltd.Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will...

News Image2 months ago - Psyence Group Inc.Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (

News Image2 months ago - Psyence Biomedical Ltd.Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that its Australian...

News Image3 months ago - Psyence Group Inc.Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc (

News Image3 months ago - Psyence Biomedical Ltd.Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

 The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic...

PBM Twits

Here you can normally see the latest stock twits on PBM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example